A federal court dismissed the litigation saying that the patent at the center of the dispute applies routine and conventional techniques to a law of nature.
The firm is seeking funding to commercialize a malondialdehyde-acetaldehyde-adduct biomarker ELISA that it believes can help broaden access to cardiac tests.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
